Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: A worldwide survey of experts

Inflammatory Bowel Diseases

Volumn 17, Issue 12, 2011, Pages 2480-2487

  Roblin, Xavier ^a   Oussalah, Abderrahim ^b,c   Chevaux, Jean Baptiste ^b,c   Sparrow, Miles ^d   Peyrin Biroulet, Laurent ^b,c  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b INSERM   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d ALFRED HOSPITAL   (Australia)

Author keywords

6 methylmercaptopurine ribonucleotides (6 MMP); 6 thioguanine nucleotides (6 TGN); azathioprine; inflammatory bowel diseases (IBD); mercaptopurine; survey; thiopurine S methyltransferase (TPMT); thiopurines

Indexed keywords

6 METHYLTHIOINOSINE; 6 THIOGUANINE NUCLEOTIDE; ALLOPURINOL; AZATHIOPRINE; GUANINE NUCLEOTIDE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CLINICAL PRACTICE; DRUG METABOLISM; ENTERITIS; ENZYME ACTIVITY; GENOTYPE; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; LIVER TOXICITY; MEDICAL EXPERT; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; REIMBURSEMENT; REVIEW;

6-MERCAPTOPURINE; AZATHIOPRINE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; GASTROENTEROLOGY; GENETIC TESTING; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; PHENOTYPE; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; WORLD HEALTH;

EID: 80052902189     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21662     Document Type: Review

References (33)

1. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006; 130: 935-939. (Pubitemid 43374542)
2. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47-53. (Pubitemid 41820634)
3. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000; 2: CD000067.
4. Prefontaine E, Sutherland LR, Macdonald JK, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009: CD000067.
5. Gisbert JP, Linares PM, McNicholl AG, et al. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009; 30: 126-137.
6. Sandborn WJ,. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996; 91: 423-433. (Pubitemid 126733803)
7. Dewit O, Starkel P, Roblin X,. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest. 2010; 13: 13.
8. Regueiro M, Mardini H,. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol. 2002; 35: 240-244. (Pubitemid 34913091)
9. Gardiner SJ, Gearry RB, Begg EJ, et al. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin Gastroenterol Hepatol. 2008; 6: 654-660.
10. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37: 674-678.
11. Gisbert JP, Gomollon F,. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008; 103: 1783-1800.
12. Gisbert JP, Nino P, Rodrigo L, et al. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006; 101: 2769-2776. (Pubitemid 44902649)
13. Gilissen LP, Derijks LJ, Bos LP, et al. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Investig. 2004; 24: 479-486. (Pubitemid 39128014)
14. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006; 55: 1423-1431. (Pubitemid 44476786)
15. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000; 118: 705-713. (Pubitemid 30171620)
16. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5: 209-214. (Pubitemid 46216945)
17. Yip JS, Woodward M, Abreu MT, et al. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis. 2008; 14: 514-518. (Pubitemid 351571831)
18. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44: 837-845.
19. Siegel CA, Sands BE,. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005; 22: 1-16. (Pubitemid 40943869)
20. Dignass A VAG, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis. 2010; 4: 28-62.
21. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol. 2009; 104: 2760-2767.
22. Leong RW, Gearry RB, Sparrow MP,. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin Drug Saf. 2008; 7: 607-616.
23. de Boer NK, Mulder CJ, van Bodegraven AA,. Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice. Aliment Pharmacol Ther. 2006; 23: 1278-1279. (Pubitemid 43779373)
24. Sparrow MP, Irving PM, Hanauer SB,. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009; 11: 496-503.
25. Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess Health Care. 2008; 24: 294-302. (Pubitemid 351950165)
26. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut. 2003; 52: 140-142. (Pubitemid 36020781)
27. Ansari A, Hassan C, Duley J, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16: 1743-1750.
28. Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2004; 2: 410-417. (Pubitemid 38561239)
29. Reinshagen M, Schutz E, Armstrong VW, et al. 6-Thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem. 2007; 53: 1306-1314. (Pubitemid 47020987)
30. Roblin X, Serre-Debeauvais F, Phelip JM, et al. 6-Thioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther. 2005; 21: 829-839. (Pubitemid 40477243)
31. Colletti RB, Baldassano RN, Milov DE, et al. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2009; 49: 297-303.
32. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100: 2239-2247.
33. Oh KT, Anis AH, Bae SC,. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology (Oxford). 2004; 43: 156-163. (Pubitemid 38219668)